Skip to content
Biodatica
Start free

ACTAVIS ELIZABETH

Location not on file

Filed/Approved
Sign in to watch

What changed

FDA approval · GABAPENTIN (ANDA203611)

3w agoFDA designationJun 23, 2026Source filing (opens the source filing in a new tab)

Momentum

55no change

Momentum 55 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Filing

    Form FDA-AP

    Jun 23, 2026

    ACTAVIS ELIZABETH · private raise, self-reported by the issuer

    SEC EDGAR · fda:ANDA203611:ORIG:1 (no direct link available for this record)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources